• 1
    NHS Scotland, Information & Statistics Division. Cervical Cytology Workload Statistics (Quarter ending 30 September 2003). Edinburgh: Information & Statistics Division, 2004. Health Briefing number 04/02.
  • 2
    NHS Cervical Screening Programme. Annual Review 2002: Building on Experience. Sheffield: NHSCSP, 2002. []. Accessed 30 January 2008.
  • 3
    Raffle AE, Alden B, Quinn M, Babb PJ, Brett MT. Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented. BMJ 2003;326:9015.
  • 4
    TOMBOLA Group. Refining the management of low-grade cervical abnormalities in the UK National Health Service, and defining the potential for HPV testing: a commentary on emerging evidence. J Low Genit Tract Dis 2006;10:2638.
  • 5
    IARC Working Group. Cervix Cancer Screening. Lyon: IARC Press, 2005.
  • 6
    Bosch FX, Iftner T. The Aetiology of Cervical Cancer. Sheffield: NHS Cancer Screening Programmes, 2005. []. Accessed 12 February 2010.
  • 7
    Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890907.
  • 8
    Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, et al. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999;1196.
  • 9
    Molden T, Nygard JF, Kraus I, Karlsen F, Nygard M, Skare GB, et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL pap smear. Int J Cancer 2005;114:9736.
  • 10
    Berkhof J, de Bruijne MC, Zielinski GD, Bulkmans NW, Rozendaal L, Snijders PJ, et al. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 2006;118:175968.
  • 11
    Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:4238.
  • 12
    Woodman CBJ, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:18316.
  • 13
    Nobbenhuis MAE, Meijer CJLM, Van Den Brule AJC, Rozendaal L, Voorhorst FJ, Risse EKJ, et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001;84:796801.
  • 14
    Koutsky L, Kiviat NB. Genital human papillomaviruses. In: Holmes K, Mardh P, Sparling P, Lemon SM, Stamm WE, Piot P, editors. Sexually Transmitted Diseases, 3rd edn. New York: McGraw-Hill; 1999. pp. 34759.
  • 15
    Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:51827.
  • 16
    Moss S, Gray A, Legood R, Vessey M, Patnick J, Kitchener H. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study. BMJ 2006;332:835.
  • 17
    Legood R, Gray A, Wolstenholme J, Moss S. Lifetime effects, costs and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies. BMJ 2006;332:7985.
  • 18
    NHS Cancer Screening Programmes. HPV Sentinel Sites Implementation Project. 2008. []. Accessed 29 January 2008.
  • 19
    Arbyn M, Buntix F, Van Ranst M. Triage of women with Atypical or Low-grade Cytological Abnormalities of the Cervix by HPV Testing: Systematic Review and Meta-analysis. Brussels: Institute of Public Health/Epidemiology, 2002. pp. 1244. Report No.: 2001-019[D/2001/2505/34].
  • 20
    Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 2005;99:S7S11.
  • 21
    ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397402.
  • 22
    ALTS Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003;188:1393400.
  • 23
    ALTS Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:138392.
  • 24
    Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). J Natl Cancer Inst 2006;98:92100.
  • 25
    Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006;95:5661.
  • 26
    Hibbitts S, Rieck GC, Hart K, Powell NG, Beukenholdt R, Dallimore N, et al. Human papillomavirus infection: an anonymous prevalence study in South Wales. Br J Cancer 2006;95:22632.
  • 27
    Cotton SC, Sharp L, Seth R, Masson LF, Little J, Cruickshank ME, et al. Lifestyle and socio-demographic factors associated with high-risk HPV infection in UK women. Br J Cancer 2007;97:1339.
  • 28
    Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Howard M, et al. Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologic abnormalities. Arch Pathol Lab Med 2003;127:116975.
  • 29
    Solomon D, Schiffman M. Have we resolved how to triage equivocal cervical cytology? J Natl Cancer Inst 2004;96:2501.
  • 30
    Rebello G, Hallam N, Smart G, Farquharson D, McCafferty J. Human papillomavirus testing and the management of women with mildly abnormal cervical smears: an observational study. BMJ 2001;322:8934.
  • 31
    Manos MM. HPV testing for clarifying borderline cervical smear results. BMJ 2001;322:8789.
  • 32
    Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Ellis N, et al. Comparison of human papillomavirus DNA testing and repeat papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. Can Med Assoc J 2000;163:7017.
  • 33
    Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for high-risk types of human papillomavirus: The HART study. Lancet 2003;362:18716.
  • 34
    Kucera E, Sliutz G, Czerwenka K, Breitenecker G, Leodolter S, Reinthaller A. Is high-risk human papillomavirus infection associated with cervical intraepithelial neoplasia eliminated after conization by large-loop excision of the transformation zone? Eur J Obstet Gynecol Reprod Biol 2001;100:726.
  • 35
    Mann CH, Steele JC, Burton A, Bailey AS, Etherington IJ, Luesley DM. LLETZ—evidence of its efficacy against HPV infection. Gynecol Oncol 2001;8:1257.
  • 36
    Sarian LO, Derchain SF, Pittal Dda R, Andrade LA, Morais SS, Figueiredo PG. Human papillomavirus detection by hybrid capture II and residual or recurrent high-grade squamous cervical intraepithelial neoplasia after large loop excision of the transformation zone (LLETZ). Tumori 2005;91:18892.
  • 37
    Jancar N, Rakar S, Poljak M, Fujs K, Kocjan BJ, Vrtacnik-Bokal E. Efficiency of three surgical procedures in eliminating high-risk human papillomavirus infection in women with precancerous cervical lesions. Eur J Gynaecol Oncol 2006;27:23942.
  • 38
    TOMBOLA Group. Cytological surveillance compared with immediate referral for colposcopy in management of women with low grade cervical abnormalities: multicentre randomised controlled trial. BMJ 2009;339:b2546.
  • 39
    The TOMBOLA Group. Biopsy and selective recall compared to immediate large loop excision in the management of women with low-grade cervical cytology referred for colposcopy. Results from the TOMBOLA multi-centre randomised controlled trial. BMJ 2009;339:b2548.
  • 40
    Cotton SC, Sharp L, Little J, Duncan I, Alexander L, Cruickshank ME, et al. Trial of management of borderline and other low-grade abnormal smears (TOMBOLA): trial design. Contemp Clin Trials 2006;27:44971.
  • 41
    The TOMBOLA Group. Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study. BMJ 2009;339:b2549.
  • 42
    Jacobs MV, Snijders PJ, van den Brule AJ. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35:7915.
  • 43
    Committee for Proprietary Medicinal Products (CPMP). Committee for proprietary medicinal products (CPMP): points to consider on adjustment for baseline covariates. Stat Med 2004;23:7019.
  • 44
    Segi M. Cancer Mortality for Selected Sites in 24 Countries (1950–1957). Japan: Tohoku University School of Medicine, 1960.
  • 45
    NHS Cervical Screening Programme. Liquid Based Cytology (LBC): The Conversion to LBC is Now Complete. Sheffield: NHS Cervical Screening Programme, 2009. []. Accessed 1 December 2009.
  • 46
    Moss SM, Gray A, Marteau T, Legood R, Henstock E, Maissi E Evaluation of HPV/LBC Cervical Screening Pilot Studies. Report to the Department of Health (revised October 2004). 2004:1307. []. Accessed 1 December 2009.
  • 47
    Kiatpongsan S, Niruthisard S, Mutirangura A, Trivijitsilp P, Vasuratna A, Chaithongwongwatthana S, et al. Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance. Int J Gynecol Cancer 2006;16:2625.
  • 48
    Andersson S, Dillner L, Elfgren K, Mints M, Persson M, Rylander E. A comparison of the human papillomavirus test and papanicolaou smear as a second screening method for women with minor cytological abnormalities. Acta Obstet Gynecol Scand 2005;84:9961000.
  • 49
    Pisal N, Sindos M, Chow C, Singer A. Triage by HPV-DNA testing: is it useful in women with persistent minor smear abnormalities? Acta Obstet Gynecol Scand 2003;82:5757.
  • 50
    Melnikow J, Nuovo J, Willan AR, Chan BKS, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;92:72735.
  • 51
    Jeronimo J, Massad LS, Schiffman M, National Institutes of Health/American Society for Colposcopy and Cervical Pathology (NIH/ASCCP) Research Group. Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. Am J Obstet Gynecol 2007;1:47.
  • 52
    Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:158997.
  • 53
    Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dilner J. Virologic versus cytologic triage of women with equivocal pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:28093.
  • 54
    Carozzi F, Cecchini S, Confortini M, Becattini V, Cariaggi MP, Pontenani G, et al. Role of P16(INK4a) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology. Cancer 2006;108:11923.
  • 55
    Giovannelli L, Capra G, Lama A, Bustinto T, Genco A, Valenti FM, et al. Atypical squamous cells of undetermined significance-favour reactive compared to atypical squamous cells of undetermined significance-favour dysplasia: association with cervical intraepithelial lesions and human papillomavirus infection. J Clin Virol 2005;33:2816.
  • 56
    Carozzi FM, Confortini M, Cecchini S, Bisanzi S, Cariaggi MP, Pontenani G, et al. Triage with human papillomavirus testing of women with cytologic abnormalities prompting referral for colposcopy assessment. Cancer Cytopathol 2005;105:27.
  • 57
    Monsonego J, Pintos J, Semaille C, Beumont M, Dachez R, Zerat L, et al. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia. Int J Gynecol Cancer 2006;16:5918.
  • 58
    Agorastos T, Miliaras D, Lambropoulos AF, Chrisafi S, Kotsis A, Manthos A, et al. Detection and typing of human papillomavirus DNA in uterine cervices with coexistent grade I and grade III intraepithelial neoplasia: biologic progression or independent lesions? Eur J Obstet Gynecol Reprod Biol 2005;121:99103.
  • 59
    Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367:48998.